



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 171151

TO: Satyanarayana Gudibande
Location: REM-3C04&3C18
Art Unit: 1654
Wednesday, November 16, 2005

Case Serial Number: 10/030944

From: Mary Hale
Location: Biotech/Chem Library
Rem 1D86
Phone: 2-2507

Mary.Hale@uspto.gov

Search Notes

Feel free to contact me if you have any questions.

Note -- results are printed on both sides of printout

This Page Blank (uspto)

Dudisande
10/030944

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.63

0.63

FILE 'REGISTRY' ENTERED AT 12:08:55 ON 16 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2005 HIGHEST RN 868125-94-4

DICTIONARY FILE UPDATES: 15 NOV 2005 HIGHEST RN 868125-94-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e rgdlldalrggg/sqep

```
E1      2      RGDLDALRG/SQEP
E2      1      RGDLDALRGG/SQEP
E3      2  --> RGDLDALRGGG/SQEP
E4      1      RGDLDALRGGGG/SQEP
E5      1      RGDLDALRGGGGG/SQEP
E6      1      RGDLDALRGGGGGG/SQEP
E7      1      RGDLDVKGIPFYKGSRA/SQEP
E8      1      RGDLDGLR/SQEP
E9      2      RGDLDGLRGGG/SQEP
E10     6      RGDLDGLR/SQEP
E11     1      RGDLEPLAARVAGR/SQEP
E12     1      RGDLEPLAARVAGR/SQEP
```

=> s e3

```
      2 RGDLDALRGGG/SQEP
85211 SQL=11
L1      2 (RGDLDALRGGG)/SQEP
```

(RGDLDALRGGG/SQEP AND SQL=11)

=> d 1-2 sqide can

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-74-8 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-
α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE cyclic

SEQ 1 ALRGGGRGDL D

=====

HITS AT: 1-6, 7-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C43 H73 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-58-8 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-
α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE cyclic

SEQ 1 ALRGGGRGDL D

HITS AT: 1-6, 7-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C43 H73 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

=> fil medl,biosis,embase,caplus;s l1
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
20.47	21.10

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 12:09:57 ON 16 NOV 2005

FILE 'BIOSIS' ENTERED AT 12:09:57 ON 16 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:09:57 ON 16 NOV 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:09:57 ON 16 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

L2	0 FILE MEDLINE
L3	0 FILE BIOSIS
L4	0 FILE EMBASE
L5	1 FILE CAPLUS

TOTAL FOR ALL FILES
L6 1 L1

=> d ibib abs hitstr

L6 ANSWER 1 OF 1 CAPLUS. COPYRIGHT-2005-ACS-on-STN

ACCESSION NUMBER: 2001:45035 CAPLUS

DOCUMENT NUMBER: 134:86549

TITLE: Preparation of cyclic peptides for use as inhibitors

of integrin $\alpha\beta 6$
 INVENTOR(S): Jonczyk, Alfred; Diefenbach, Beate; Goodman, Simon
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: Ger. Offen., 20 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

APM (out)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19933173	A1	20010118	DE 1999-19933173	19990715
CA 2379022	AA	20010125	CA 2000-2379022	20000703
WO 2001005810	A2	20010125	WO 2000-EP6188	20000703
WO 2001005810	A3	20010517		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000012418	A	20020326	BR 2000-12418	20000703
EP 1196433	A2	20020417	EP 2000-943971	20000703
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2003505395	T2	20030212	JP 2001-511467	20000703
AU 772782	B2	20040506	AU 2000-58236	20000703
NO 2002000176	A	20020114	NO 2002-176	20020114
ZA 2002001275	A	20030822	ZA 2002-1275	20020214
PRIORITY APPLN. INFO.:			DE 1999-19933173	A 19990715
			WO 2000-EP6188	W 20000703

OTHER SOURCE(S): MARPAT 134:86549

AB Title compds. cyclo(Arg-X1-Asp-X2-X3-X4-X5-X6-R1) [(I); X1 = Ser, Gly, Thr; X2 = Leu, Ile, Nle, Val, Phe; X3 = Asp, Glu, Lys, Phe; X4 = Gly, Ala, Ser; X5 = Leu, Ile, Nle, Val, Phe; X6 = Arg, Har, Lys; R1 = absent, one or more ω -amino-carboxy acid residues; all amino acids may be either D- or L-configuration] were prepared using solid-phase peptide synthesis and tested for activity as integrin $\alpha\beta 6$ inhibitors for therapeutic use. Thus thirty-three I compds. were synthesized on chlorotrityl-polystyrol resin and tested for their binding capacities with the $\alpha\beta 6$ fibronectin receptor. Q-values for the tests (Q = IC50 I/IC50 reference peptide) (reference peptide =

Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NH2; 75 nM) ranged from 233 to 0.014.

IT 317366-58-8P 317366-74-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of cyclic peptides for use as inhibitors of integrin $\alpha\beta 6$ in treatment of)

RN 317366-58-8 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







RN 317366-74-8 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-L- α -aspartyl) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C



=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.06

29.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.73

-0.73

FILE 'REGISTRY' ENTERED AT 12:10:19 ON 16 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 NOV 2005 HIGHEST RN 868125-94-4
DICTIONARY FILE UPDATES: 15 NOV 2005 HIGHEST RN 868125-94-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s r[sgt]d[lixvf] [dekf] [gas] [lixvf] [rxk]/sqsp
L7      294 R[SGT]D[LIXVF] [DEKF] [GAS] [LIXVF] [RXK]/SQSP
```

```
=> s l7(l) (cyclo or cyclic)
      3747558 CYCLO
      38 CYCLOS
      3747558 CYCLO
      (CYCLO OR CYCLOS)
      94190 CYCLIC
L8      0 L7(L) (CYCLO OR CYCLIC)
      ;
```

```
=> s l7(l) (d or l)
      7686897 D
      1934043 L
L9      0 L7(L) (D OR L)
      ;
```

```
=> e rgdlldglrggg/sqep 5
E1      1      RGDLDVKGIPFYKGSRA/SQEP
E2      1      RGDLDGLR/SQEP
E3      2 --> RGDLDGLRGGG/SQEP
E4      6      RGDLDGLR/SQEP
E5      1      RGDLEPLAARVAGR/SQEP
```

```
=> s e3;e rgdlaalrggg/sqep 5
      2 RGDLDGLRGGG/SQEP
      85211 SQL=11
```

```
L10          2 (RGDLDGLRGGG)/SQEP
              (RGDLDGLRGGG/SQEP AND SQL=11)

E1           1      RGDLAIVQRLSNRL/SQEP
E2           1      RGDLAIVQRLSNRLC/SQEP
E3           1 -->  RGDLAALRGGG/SQEP
E4           1      RGDLAALSAPPV/SQEP
E5           1      RGDLAFRDDSIWPQEEPAIRPRSSQVRVLPNGIQHSEKLNRTCCNLGGACMLESFACPPS
              FYGRNCEHDVRKENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVA
              SRTPELPPS/SQEP
```

```
=> s e3;e rtdldalrggg/sqep 5
          1 RGDLAALRGGG/SQEP
      85211 SQL=11
L11       1 (RGDLAALRGGG)/SQEP
          (RGDLAALRGGG/SQEP AND SQL=11)
```

```
E1           2      RTDLDALR'OAA'/SQEP
E2           2      RTDLDALR'OAA-OAA'/SQEP
E3           2 -->  RTDLDALRGGG/SQEP
E4           2      RTDLDGLR/SQEP
E5           2      RTDLDGLRGGG/SQEP
```

```
=> s e3;e rgdldalrxx/sqep 5
          2 RTDLDALRGGG/SQEP
      85211 SQL=11
L12       2 (RTDLDALRGGG)/SQEP
          (RTDLDALRGGG/SQEP AND SQL=11)
```

```
E1           1      RGDLDALRGGGGG/SQEP
E2           1      RGDLDALRGGGGGG/SQEP
E3           0 -->  RGDLDALRXX/SQEP
E4           1      RGDLDVKGIPFYKGSRA/SQEP
E5           1      RGDLDGLR/SQEP
```

```
=> e rgdldalr/sqep 5
E1           1      RGDLCQEWASGCNTRCRGHHRPCTHL/SQEP
E2           1      RGDLD'BAL'LR/SQEP
E3           2 -->  RGDLDALR/SQEP
E4           1      RGDLDALR'BAL-BAL'/SQEP
E5           3      RGDLDALR'OAA'/SQEP
```

```
=> s e3
          2 RGDLDALR/SQEP
      66848 SQL=8
L13       2 (RGDLDALR)/SQEP
          (RGDLDALR/SQEP AND SQL=8)
```

```
=> e rtdldalr/sqep 5
E1           1      RTDLD'BAL'LR/SQEP
E2           1      RTDLD'OAA'LR/SQEP
E3           2 -->  RTDLDALR/SQEP
E4           2      RTDLDALR'OAA'/SQEP
E5           2      RTDLDALR'OAA-OAA'/SQEP
```

```
=> s e3
          2 RTDLDALR/SQEP
```

66848 SQL=8
 L14 2 (RTDLDALR)/SQEP
 (RTDLDALR/SQEP AND SQL=8)

=> e rtdldalra/sqep 5

E1 2 RTDLDALR'OAA'/SQEP
 E2 2 RTDLDALR'OAA-OAA'/SQEP
 E3 0 --> RTDLDALRA/SQEP
 E4 2 RTDLDALRGGG/SQEP
 E5 2 RTDLDGRLR/SQEP

=> e rgdldalra/sqep 5

E1 3 RGDLDALR'OAA'/SQEP
 E2 1 RGDLDALR'OAA-OAA'/SQEP
 E3 0 --> RGDLDALRA/SQEP
 E4 2 RGDLDALRG/SQEP
 E5 1 RGDLDALRGG/SQEP

=> s l10 or l11 or l12 or l13 or l14

L15 9 L10 OR L11 OR L12 OR L13 OR L14

=> d 1-9 sqide can;fil caplus;s l15

L15 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN

RN 527744-99-6 REGISTRY

CN L-Argininamide, N2-acetyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 8

NTE modified

type	location	description
terminal mod.	Arg-1	N-acetyl
terminal mod.	Arg-8	C-terminal amide

SEQ 1 RGDLDALR
 =====

HITS AT: 1-8

MF C39 H69 N15 O13

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Conference


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:385705

L15 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-75-9 REGISTRY
CN Cyclo(L-arginylglycyl-L- α -aspartyl-L-leucyl-L- α -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE cyclic

SEQ 1 RGDLDGLRGG G
===== =
HITS AT: 1-11


RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C42 H71 N17 O15

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-73-7 REGISTRY
 CN Cyclo(L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Page 15

SQL 11
NTE cyclic

SEQ 1 RGDLDGLRGG G

=====

HITS AT: 1-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C42 H71 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-67-9 REGISTRY

CN Cyclo(D-alanyl-L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 11

NTE cyclic

SEQ 1 AALRGGGRGD L

=====

HITS AT: 1-7, 8-11

MF C42 H73 N17 O13

SR CA


LC STN Files: CA, CAPLUS


DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-63-5 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-
 α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 11
 NTE cyclic

SEQ 1 ALRGGGRTDL D
 ===== =
 HITS AT: 1-6, 7-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C45 H77 N17 O16

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
 (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-61-3 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-
α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE cyclic

SEQ 1 ALRGGGRDLD

=====

HITS AT: 1-6, 7-11

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C45 H77 N17 O16

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549


L15 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-53-3 REGISTRY

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 8
 NTE cyclic

SEQ 1 ALRRGDLD
 =====
 HITS AT: 1-3, 4-8
 MF C37 H64 N14 O12
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-50-0 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 8
 NTE cyclic

SEQ 1 ALRRTDLD
 =====
 HITS AT: 1-3, 4-8
 MF C39 H68 N14 O13
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L15 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2005 ACS on STN
RN 313246-44-5 REGISTRY
CN L-Argininamide, N2-acetyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-L- α -aspartyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE modified

type	location	description
terminal mod.	Arg-1	N-acetyl
terminal mod.	Arg-8	C-terminal amide

SEQ 1 RTDLDALR
=====

HITS AT: 1-8

MF C41 H73 N15 O14

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:42449

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	141.87	171.03
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

FILE 'CAPLUS' ENTERED AT 12:16:33 ON 16 NOV 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Nov 2005 VOL 143 ISS 21
FILE LAST UPDATED: 15 Nov 2005 (20051115/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

L16 3 L15

=> d 1-3 ibib abs hitseq

L16 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:692564 CAPLUS
DOCUMENT NUMBER: 138:385705
TITLE: Linear and cyclic peptides for integrin α v β 6 inhibition
AUTHOR(S): Zischinsky, Gunther; Groth, Ulrich; Diefenbach, Beate; Jonczyk, Alfred
CORPORATE SOURCE: Faculty of Chemistry, University of Konstanz, Germany
SOURCE: Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001 (2001), 733-734. Editor(s): Lebl, Michal; Houghten, Richard A. American Peptide Society: San Diego, Calif.
CODEN: 69DBAL; ISBN: 0-9715560-0-8
DOCUMENT TYPE: Conference
LANGUAGE: English
AB A symposium report. Integrin α v β 6 inhibitory activity of peptides was enhanced by cyclization, which increased rigidity and proteolytic stability. The best linear derivative was the non-RGD peptide Ac-TRDLdSLR-NH₂. Selected cyclic peptides proved to be stable in human blood plasma with half life-times of more than 30 h.
IT 527744-99-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(linear and cyclic peptides as inhibitors of integrin α v β 6)
RN 527744-99-6 CAPLUS
CN L-Argininamide, N₂-acetyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 RGDLDALR

Absolute stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

28 143/48/23


U30

Appuzak

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:45035 CAPLUS

DOCUMENT NUMBER: 134:86549

TITLE: Preparation of cyclic peptides for use as inhibitors of integrin $\alpha v \beta 6$

INVENTOR(S): Jonczyk, Alfred; Diefenbach, Beate; Goodman, Simon

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Ger. Offen., 20 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19933173	A1	20010118	DE 1999-19933173	19990715
CA 2379022	AA	20010125	CA 2000-2379022	20000703
WO 2001005810	A2	20010125	WO 2000-EP6188	20000703

WO 2001005810 A3 20010517
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
BR 2000012418 A 20020326 BR 2000-12418 20000703
EP 1196433 A2 20020417 EP 2000-943971 20000703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2003505395 T2 20030212 JP 2001-511467 20000703
AU 772782 B2 20040506 AU 2000-58236 20000703
NO 2002000176 A 20020114 NO 2002-176 20020114
ZA 2002001275 A 20030822 ZA 2002-1275 20020214
PRIORITY APPLN. INFO.: DE 1999-19933173 A 19990715
WO 2000-EP6188 W 20000703
OTHER SOURCE(S): MARPAT 134:86549
AB Title compds. cyclo(Arg-X1-Asp-X2-X3-X4-X5-X6-R1) [(I); X1 = Ser, Gly,
Thr; X2 = Leu, Ile, Nle, Val, Phe; X3 = Asp, Glu, Lys, Phe; X4 = Gly, Ala,
Ser; X5 = Leu, Ile, Nle, Val, Phe; X6 = Arg, Har, Lys; R1 = absent, one or
more ω -amino-carboxy acid residues; all amino acids may be either D-
or L-configuration] were prepared using solid-phase peptide synthesis and
tested for activity as integrin $\alpha v \beta 6$ inhibitors for therapeutic
use. Thus thirty-three I compds. were synthesized on chlorotrityl-
polystyrol resin and tested for their binding capacities with the
 $\alpha v \beta 6$ fibronectin receptor. Q-values for the tests (Q = IC50
I/IC50 reference peptide) (reference peptide =
Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-
NH2; 75 nM) ranged from 233 to 0.014.
IT 317366-50-0P 317366-53-3P 317366-61-3P
317366-63-5P 317366-67-9P 317366-73-7P
317366-75-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic peptides for use as inhibitors of integrin
 $\alpha v \beta 6$ in treatment of)
RN 317366-50-0 CAPLUS
CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-threonyl-L- α -aspartyl-
L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)
NTE cyclic
SEQ 1 ALRRTDLD

Absolute stereochemistry.




RN 317366-53-3 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRRGDLD



RN 317366-61-3 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGRTDL D

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-63-5 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-alpha-aspartyl-L-leucyl-L-alpha-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGRTDL D

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 317366-67-9 CAPLUS
 CN Cyclo(D-alanyl-L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl) (9CI) (CA INDEX NAME)
 NTE cyclic
 SEQ 1 AALRGGGRGD L

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-73-7 CAPLUS


CN Cyclo(L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 RGDLDGLRGG G

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 317366-75-9 CAPLUS
 CN Cyclo(L-arginylglycyl-L- α -aspartyl-L-leucyl-L- α -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)
 NTE cyclic
 SEQ 1 RGDLDGLRGG G

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L16 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:909678 CAPLUS

DOCUMENT NUMBER: 134:42449

TITLE: Synthesis of peptide inhibitors of integrin $\alpha v \beta 6$

INVENTOR(S): Jonczyk, Alfred; Diefenbach, Beate; Groth, Ulrich; Zischinsky, Gunther

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Ger. Offen., 34 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Applicant


DE 19929410	A1	20001228	DE 1999-19929410	19990626
CA 2377224	AA	20010104	CA 2000-2377224	20000613
WO 2001000660	A1	20010104	WO 2000-EP5404	20000613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1189930	A1	20020327	EP 2000-949177	20000613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000011954	A	20020507	BR 2000-11954	20000613
JP 2003503422	T2	20030128	JP 2001-507066	20000613
AU 771099	B2	20040311	AU 2000-62630	20000613
NO 2001006341	A	20020225	NO 2001-6341	20011221
ZA 2002000673	A	20030424	ZA 2002-673	20020124
PRIORITY APPLN. INFO.:			DE 1999-19929410	A 19990626
			WO 2000-EP5404	W 20000613
OTHER SOURCE(S): MARPAT 134:42449				
AB	The invention describes the solid-phase synthesis of peptides H3CC(O)-Arg-X1-Asp-X2-X3-X4-X5-X6-NH2 [(I); X1 = Ser, Gly, Thr, Asp, Arg, Val, Tyr, His or Ala; X2 = Leu, Ile, Nle, Val or Phe; X3 = Asp, Glu, Lys, Phe, Aib, Nal, Gly, Ala, Bgl or Phg; X4 = Gly, Ala, Ser, β Ala or ω Abu; X5 = Leu, Ile, Nle, Val, Phe; X6 = Arg, Har, Lys, Leu, Orn, Phe, Ala, Tyr, Gly, Ser or Asp] for use as inhibitors of α v β 6 integrin in the treatment of disease. Thus I [X1 = Gly; X2 = Leu; X3 = D-Asp; X4 = Ser; X5 = Leu; X6 = Arg (II)] was synthesized using solid-phase techniques. In in vitro binding tests, using peptide H3CC(O)-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NH2 as standard, II had Q-value (IC50 test peptide/IC50 standard) 0.15 at 75 nM.			
IT	313246-44-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of peptide inhibitors of integrin α v β 6 for treatment of disease)			
RN	313246-44-5 CAPLUS			
CN	L-Argininamide, N2-acetyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-L- α -aspartyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)			
NTE	modified			
SEQ	1 RTDLDALR			

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



=> dis his

(FILE 'HOME' ENTERED AT 12:06:59 ON 16 NOV 2005)

FILE 'REGISTRY' ENTERED AT 12:08:55 ON 16 NOV 2005

E RGDLDALRGGG/SQEP

L1 2 S E3

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 12:09:57 ON 16 NOV 2005

L2 0 FILE MEDLINE

L3 0 FILE BIOSIS

L4 0 FILE EMBASE

L5 1 FILE CAPLUS

TOTAL FOR ALL FILES

L6 1 S L1

FILE 'REGISTRY' ENTERED AT 12:10:19 ON 16 NOV 2005

L7 294 S R[SGT]D[LIXVF][DEKF][GAS][LIXVF][RXK]/SQSP

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

L8 0 S L7 (L) (CYCLO OR CYCLIC)
 L9 0 S L7 (L) (D OR L)
 E RGDLDGLRGGG/SQEP 5
 L10 2 S E3
 E RGDLAALRGGG/SQEP 5
 L11 1 S E3
 E RTDLDALRGGG/SQEP 5
 L12 2 S E3
 E RGDLDALRXX/SQEP 5
 E RGDLDALR/SQEP 5
 L13 2 S E3
 E RTDLDALR/SQEP 5
 L14 2 S E3
 E RTDLDALRA/SQEP 5
 E RGDLDALRA/SQEP 5
 L15 9 S L10 OR L11 OR L12 OR L13 OR L14

FILE 'CAPLUS' ENTERED AT 12:16:33 ON 16 NOV 2005
 L16 3 S L15

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	28.86	199.89
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.19	-2.92

STN INTERNATIONAL LOGOFF AT 12:17:14 ON 16 NOV 2005

Page 1

=> s r[sgt]d[lixvf][dekf][gas][lixvf][rxk]/sqsp
L1 296 R[SGT]D[LIXVF][DEKF][GAS][LIXVF][RXK]/SQSP

=> s cyclic/nte
L2 27096 CYCLIC/NTE

=> s l1 and l2
L3 30 L1 AND L2

=> d 1-30 sqide can

L3 ANSWER 1 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-80-6 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-4-aminobutanoyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI)
(CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10
NTE cyclic

type	location	description
uncommon	Oaa-4	-
uncommon	Oaa-5	-

SEQ 1 ALRXXRTDLD

=== =====

HITS AT: 1-3, 6-10

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C47 H82 N16 O15

SR CA


LC STN Files: CA, CAPLUS


DT.CA CAPLUS document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 2 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-79-3 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-6-aminohexanoyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI)
(CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 10

NTE **cyclic**

type	location	description
uncommon	Oaa-4	-
uncommon	Oaa-5	-

SEQ 1 ALRXXRTDLD

=== =====

HITS AT: 1-3, 6-10

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C51 H90 N16 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-78-2 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-L-arginylglycyl-L-
 α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 9
 NTE **cyclic**

type	location	description
uncommon	Oaa-4	-

SEQ 1 ALRXRGDLD

====

HITS AT: 1-3, 5-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK


MF C41 H71 N15 O13

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-77-1 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9

NTE **cyclic**

type	location	description
uncommon	Oaa-4	-

SEQ 1 ALRXRTDLD

=== =====

HITS AT: 1-3, 5-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C43 H75 N15 O14

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-76-0 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-threonyl-L-
 α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 9
 NTE **cyclic**

type	location	description
uncommon	Oaa-4	-

SEQ 1 ALRXRTDLD

====

HITS AT: 1-3, 5-9

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C45 H79 N15 O14

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-75-9 REGISTRY

CN Cyclo(L-arginylglycyl-L- α -aspartyl-L-leucyl-L- α -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Page 7

FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE **cyclic**

SEQ 1 RGDLDGLRGG G

HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C42 H71 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-74-8 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-
α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE **cyclic**

SEQ 1 ALRGGGRGDL D

=== =====

HITS AT: 1-3, 7-11

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C43 H73 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-73-7 REGISTRY
CN Cyclo(L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE **cyclic**

SEQ 1 RGDLDGLRGG G

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

=====

HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C42 H71 N17 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 134:86549

L3 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-72-6 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 13
 NTE **cyclic**


SEQ 1 ALRGGGGGRG DLD
 === == ===
 HITS AT: 1-3, 9-13
 MF C47 H79 N19 O17
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAPLUS document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-71-5 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 12
 NTE **cyclic**

SEQ 1 ALRGGGGGRGD LD
 === == ==

HITS AT: 1-3, 8-12

MF C45 H76 N18 O16

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-70-4 REGISTRY
 CN Cyclo[[2-(2-aminoethoxy)ethoxy]acetyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl-L-alanyl-L-leucyl-L-arginyl] (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 9
 NTE **cyclic**

type	location	description
------	----------	-------------

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

uncommon	Oaa-4	-	-
stereo	Asp-9	-	D

SEQ 1 ALRXRGDLD

=== =====

HITS AT: 1-3, 5-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C43 H75 N15 O15

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-69-1 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-L-arginylglycyl-L-
 α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 9
 NTE **cyclic**

type	location	description
uncommon	Oaa-4	-

SEQ 1 ALRXRGDLD
 === =====

HITS AT: 1-3, 5-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C43 H75 N15 O13

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-68-0 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-6-aminohexanoyl-L-

arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA
INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 10

NTE **cyclic**

type	location	description
uncommon	Oaa-4	-
uncommon	Oaa-5	-

SEQ 1 ALRXXRGDLD

=== =====

HITS AT: 1-3, 6-10

MF C49 H86 N16 O14

SR CA


LC STN Files: CA, CAPLUS


DT.CA CAPLUS document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 134:86549

L3 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-65-7 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 9
 NTE **cyclic**

SEQ 1 ALRGRGDLD
 === =====
 HITS AT: 1-3, 5-9

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C39 H67 N15 O13
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-64-6 REGISTRY
CN Cyclo(L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-α-aspartyl-L-leucyl-L-α-aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE **cyclic**


SEQ 1 RGGGRTDLDG L
= =====
HITS AT: 1, 5-11

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****


MF C44 H75 N17 O16
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-63-5 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-
α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE **cyclic**

SEQ 1 ALRGGGRTDL D
==== =
HITS AT: 1-3, 7-11

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C45 H77 N17 O16

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-62-4 REGISTRY

CN Cyclo(L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-α-aspartyl-

L-leucyl-D-α-aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 11
 NTE **cyclic**

SEQ 1 RGGGRTDLDG L

= =====

HITS AT: 1, 5-11

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C44 H75 N17 O16

SR CA


LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-61-3 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-
α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE cyclic

SEQ 1 ALRGGGRTDL D
==== =====
HITS AT: 1-3, 7-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C45 H77 N17 O16

SR CA


LC STN Files: CA, CAPLUS


DT.CA CAPLUS document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-60-2 REGISTRY
 CN Cyclo(β -alanyl- β -alanyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl-L-alanyl-L-leucyl-L-arginyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 10
 NTE **cyclic**

type	-----	location	-----	description
uncommon	Bal-4	-	-	
uncommon	Bal-5	-	-	

SEQ 1 ALRXXRGDLD

==== =====

HITS AT: 1-3, 6-10

MF C43 H74 N16 O14

SR CA


LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-59-9 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 14

NTE **cyclic**

SEQ 1 ALRGGGGGGR GDLD

==== = =====

HITS AT: 1-3, 10-14


MF C49 H82 N20 O18

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

L3 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-58-8 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-
α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE **cyclic**


SEQ 1 ALRGGGRGDL D
=== =====
HITS AT: 1-3, 7-11

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****


MF C43 H73 N17 O15
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAPLUS document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 317366-57-7 REGISTRY
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 10
 NTE **cyclic**


SEQ 1 ALRGGRGDLD

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


==== =====
HITS AT: 1-3, 6-10
MF C41 H70 N16 O14
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAPLUS document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-56-6 REGISTRY
CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9
NTE **cyclic**

SEQ 1 ALRGRGDLD
=====
HITS AT: 1-3, 5-9

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C39 H67 N15 O13


SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Conference; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:385705

REFERENCE 2: 134:86549

L3 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-54-4 REGISTRY

CN Cyclo(L-arginyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 8

NTE **cyclic**

SEQ 1 RRGDLGL
=====

HITS AT: 1, 2-8

MF C36 H62 N14 O12


SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES

(Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-53-3 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 8

NTE **cyclic**

SEQ 1 ALRRGDLD

=====

HITS AT: 1-3, 4-8


MF C37 H64 N14 O12

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-52-2 REGISTRY
CN Cyclo(L-arginyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -
aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE **cyclic**

SEQ 1 RRGDLDSL

=====

HITS AT: 1, 2-8

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****


MF C37 H64 N14 O13

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-51-1 REGISTRY
CN Cyclo(L-arginyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-L- α -
aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE **cyclic**

SEQ 1 RRGDLDSL

=====

HITS AT: 1, 2-8

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****


MF C37 H64 N14 O13

SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 317366-50-0 REGISTRY

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 8

NTE **cyclic**

SEQ 1 ALRRTDLD

=====

HITS AT: 1-3, 4-8

MF C39 H68 N14 O13


SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-49-7 REGISTRY
CN Cyclo(L-arginyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -
aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE **cyclic**

SEQ 1 RRTDLDSL
=====

HITS AT: 1, 2-8

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C39 H68 N14 O14


SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

L3 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 317366-48-6 REGISTRY
CN Cyclo(L-arginyl-L-arginyl-L-threonyl-L-α-aspartyl-L-leucyl-L-α-aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 8
NTE **cyclic**

SEQ 1 RRTDLDSL

=====

HITS AT: 1, 2-8

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF C39 H68 N14 O14


SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:86549

=> fil medl,biosis,embase,caplus;
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
224.79	225.00

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 08:33:23 ON 30 NOV 2005

FILE 'BIOSIS' ENTERED AT 08:33:23 ON 30 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 08:33:23 ON 30 NOV 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 08:33:23 ON 30 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> s zischinsky g?/au;s groth u?/au;s diefenbach b?/au;s jonczyk a?/au
L4 0 FILE MEDLINE
L5 0 FILE BIOSIS
L6 0 FILE EMBASE
L7 8 FILE CAPLUS

TOTAL FOR ALL FILES
L8 8 ZISCHINSKY G?/AU

L9 28 FILE MEDLINE
L10 56 FILE BIOSIS
L11 33 FILE EMBASE
L12 89 FILE CAPLUS

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

TOTAL FOR ALL FILES
L13 206 GROTH U?/AU

L14 10 FILE MEDLINE
L15 22 FILE BIOSIS
L16 9 FILE EMBASE
L17 44 FILE CAPLUS

TOTAL FOR ALL FILES
L18 85 DIEFENBACH B?/AU

L19 34 FILE MEDLINE
L20 71 FILE BIOSIS
L21 72 FILE EMBASE
L22 270 FILE CAPLUS

TOTAL FOR ALL FILES
L23 447 JONCZYK A?/AU

=> s l8 and l13 and l18 and l23
L24 0 FILE MEDLINE
L25 0 FILE BIOSIS
L26 0 FILE EMBASE
L27 4 FILE CAPLUS

TOTAL FOR ALL FILES
L28 4 L8 AND L13 AND L18 AND L23

=> s l3 not l28
L29 0 FILE MEDLINE
L30 0 FILE BIOSIS
L31 0 FILE EMBASE
L32 1 FILE CAPLUS

TOTAL FOR ALL FILES
L33 1 L3 NOT L28


=> d ibib abs hitseq

L33 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:45035 CAPLUS
DOCUMENT NUMBER: 134:86549
TITLE: Preparation of cyclic peptides for use as inhibitors
of integrin $\alpha\beta 6$
INVENTOR(S): Jonczyk, Alfred; Diefenbach, Beate; Goodman, Simon
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

DE 19933173	A1	20010118	DE 1999-19933173	19990715
CA 2379022	AA	20010125	CA 2000-2379022	20000703
WO 2001005810	A2	20010125	WO 2000-EP6188	20000703
WO 2001005810	A3	20010517		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012418	A	20020326	BR 2000-12418	20000703
EP 1196433	A2	20020417	EP 2000-943971	20000703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003505395	T2	20030212	JP 2001-511467	20000703
AU 772782	B2	20040506	AU 2000-58236	20000703
NO 2002000176	A	20020114	NO 2002-176	20020114
ZA 2002001275	A	20030822	ZA 2002-1275	20020214
PRIORITY APPLN. INFO.:			DE 1999-19933173	A 19990715
			WO 2000-EP6188	W 20000703
OTHER SOURCE(S): MARPAT 134:86549				
AB Title compds. cyclo(Arg-X1-Asp-X2-X3-X4-X5-X6-R1) [(I); X1 = Ser, Gly, Thr; X2 = Leu, Ile, Nle, Val, Phe; X3 = Asp, Glu, Lys, Phe; X4 = Gly, Ala, Ser; X5 = Leu, Ile, Nle, Val, Phe; X6 = Arg, Har, Lys; R1 = absent, one or more ω -amino-carboxy acid residues; all amino acids may be either D- or L-configuration] were prepared using solid-phase peptide synthesis and tested for activity as integrin $\alpha\text{v}\beta 6$ inhibitors for therapeutic use. Thus thirty-three I compds. were synthesized on chlorotriptyl-polystyrol resin and tested for their binding capacities with the $\alpha\text{v}\beta 6$ fibronectin receptor. Q-values for the tests (Q = IC50 I/IC50 reference peptide) (reference peptide =				
Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NH2; 75 nM) ranged from 233 to 0.014.				
IT	317366-48-6P 317366-49-7P 317366-50-0P 317366-51-1P 317366-52-2P 317366-53-3P 317366-54-4P 317366-56-6P 317366-57-7P 317366-58-8P 317366-59-9P 317366-60-2P 317366-61-3P 317366-62-4P 317366-63-5P 317366-64-6P 317366-65-7P 317366-68-0P 317366-69-1P 317366-70-4P 317366-71-5P 317366-72-6P 317366-73-7P 317366-74-8P 317366-75-9P 317366-76-0P 317366-77-1P 317366-78-2P 317366-79-3P 317366-80-6P			
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of cyclic peptides for use as inhibitors of integrin $\alpha\text{v}\beta 6$ in treatment of)				
RN	317366-48-6 CAPLUS			
CN	Cyclo(L-arginyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-L- α -aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)			
NTE cyclic				
SEQ	1 RRTDLDL			

Absolute stereochemistry.




RN 317366-49-7 CAPLUS

CN Cyclo(L-arginyl-L-arginyl-L-threonyl-L-α-aspartyl-L-leucyl-D-α-aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRTDLDL

Absolute stereochemistry.



RN 317366-50-0 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-threonyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

SEQ 1 ALRRTDLD

Absolute stereochemistry.




RN 317366-51-1 CAPLUS

CN Cyclo(L-arginyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-L- α -aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRGDLDSL




RN 317366-52-2 CAPLUS

CN Cyclo(L-arginyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl-L-seryl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRGDLDSL




RN 317366-53-3 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRRGDLD




RN 317366-54-4 CAPLUS

CN Cyclo(L-arginyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RRGDLGL




RN 317366-56-6 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRGRGDLD



RN 317366-57-7 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGRGDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-58-8 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-
α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGRGDL D


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 317366-59-9 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycylglycylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRGGGGGGR GDLD

Absolute stereochemistry.






RN 317366-60-2 CAPLUS


CN Cyclo(β -alanyl- β -alanyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl-L-alanyl-L-leucyl-L-arginyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRXXRGDLD

Absolute stereochemistry.






RN 317366-61-3 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRGGGRTDL D

Absolute stereochemistry.



PAGE 1-B



RN 317366-62-4 CAPLUS


CN Cyclo(L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L-α-aspartyl-L-leucyl-D-α-aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 RGGGRTDLDG L

Absolute stereochemistry.

PAGE 1-A






RN 317366-63-5 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-L- α -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRGGGRTDL D

Absolute stereochemistry.






RN 317366-64-6 CAPLUS


CN Cyclo(L-arginylglycylglycylglycyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-L- α -aspartylglycyl-L-leucyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RGGGRTDLDG L

Absolute stereochemistry.






RN 317366-65-7 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-L- α -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRGRGDLD



RN 317366-68-0 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-6-aminohexanoyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXXRGDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 317366-69-1 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-L-arginylglycyl-L-
α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRXRGDLD


Absolute stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PAGE 1-A



PAGE 1-B



RN 317366-70-4 CAPLUS


CN Cyclo[[2-(2-aminoethoxy)ethoxy]acetyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl-L-alanyl-L-leucyl-L-arginyl] (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXRGDLD


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







RN 317366-71-5 CAPLUS
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRGGGGRGD LD

Absolute stereochemistry.






RN 317366-72-6 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-α-aspartyl-L-leucyl-D-α-aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRGGGGGRG DLD


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C



RN 317366-73-7 CAPLUS


CN Cyclo(L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 RGDLDGLRGG G

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 317366-74-8 CAPLUS
 CN Cyclo(L-alanyl-L-leucyl-L-arginylglycylglycylglycyl-L-arginylglycyl-L-
 α-aspartyl-L-leucyl-L-α-aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRGGGRGDL D


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 317366-75-9 CAPLUS


CN Cyclo(L-arginylglycyl-L- α -aspartyl-L-leucyl-L- α -aspartylglycyl-L-leucyl-L-arginylglycylglycylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 RGDLDGLRGG G

Absolute stereochemistry.






RN 317366-76-0 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRXRTDLD

Absolute stereochemistry.



PAGE 1-B



RN 317366-77-1 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)


NTE cyclic

SEQ 1 ALRXRTDLD

Absolute stereochemistry.

PAGE 1-A






RN 317366-78-2 CAPLUS

CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-L-arginylglycyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 ALRXRGDLD



RN 317366-79-3 CAPLUS


CN Cyclo(L-alanyl-L-leucyl-L-arginyl-6-aminohexanoyl-6-aminohexanoyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI) (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXXRTDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 317366-80-6 CAPLUS
 CN Cyclo(L-alanyl-L-leucyl-L-arginyl-4-aminobutanoyl-4-aminobutanoyl-L-arginyl-L-threonyl-L- α -aspartyl-L-leucyl-D- α -aspartyl) (9CI)
 (CA INDEX NAME)

NTE cyclic


SEQ 1 ALRXXRTDLD

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=> s l3 not (l8 or l13 or l18 or l23)

L34 0 FILE MEDLINE

L35 0 FILE BIOSIS

L36 0 FILE EMBASE

L37 0 FILE CAPLUS

TOTAL FOR ALL FILES

L38 0 L3 NOT (L8 OR L13 OR L18 OR L23)

=> dis his

(FILE 'HOME' ENTERED AT 08:31:16 ON 30 NOV 2005)

FILE 'REGISTRY' ENTERED AT 08:31:25 ON 30 NOV 2005

L1 296 S R[SGT]D[LIXVF] [DEKF] [GAS] [LIXVF] [RXK]/SQSP

L2 27096 S CYCLIC/NTE

L3 30 S L1 AND L2

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 08:33:23 ON 30 NOV 2005

```

L4          0 FILE MEDLINE
L5          0 FILE BIOSIS
L6          0 FILE EMBASE
L7          8 FILE CAPLUS
TOTAL FOR ALL FILES
L8          8 S ZISCHINSKY G?/AU
L9          28 FILE MEDLINE
L10         56 FILE BIOSIS
L11         33 FILE EMBASE
L12         89 FILE CAPLUS
TOTAL FOR ALL FILES
L13         206 S GROTH U?/AU
L14         10 FILE MEDLINE
L15         22 FILE BIOSIS
L16         9 FILE EMBASE
L17         44 FILE CAPLUS
TOTAL FOR ALL FILES
L18         85 S DIEFENBACH B?/AU
L19         34 FILE MEDLINE
L20         71 FILE BIOSIS
L21         72 FILE EMBASE
L22        270 FILE CAPLUS
TOTAL FOR ALL FILES
L23        447 S JONCZYK A?/AU
L24         0 FILE MEDLINE
L25         0 FILE BIOSIS
L26         0 FILE EMBASE
L27         4 FILE CAPLUS
TOTAL FOR ALL FILES
L28         4 S L8 AND L13 AND L18 AND L23
L29         0 FILE MEDLINE
L30         0 FILE BIOSIS
L31         0 FILE EMBASE
L32         1 FILE CAPLUS
TOTAL FOR ALL FILES
L33         1 S L3 NOT L28
L34         0 FILE MEDLINE
L35         0 FILE BIOSIS
L36         0 FILE EMBASE
L37         0 FILE CAPLUS
TOTAL FOR ALL FILES
L38         0 S L3 NOT (L8 OR L13 OR L18 OR L23)

```

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	24.08	249.08
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

STN INTERNATIONAL LOGOFF AT 08:36:47 ON 30 NOV 2005